Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
Jacob P. Laubach(Harvard University), Paul G. Richardson(Harvard University), Árpád Illés(University of Debrecen), Pierre Maison‐Blanche(Inserm), Jesús F. San Miguel(Clinica Universidad de Navarra), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Sagar Lonial(Emory University), Tomasz Wróbel, Ivan Špıčka(Charles University), Joan Bladé(Hospital Clínic de Barcelona), Lutz Jacobasch(Orthopädische Praxis), Meral Beksaç(Ankara University), Meletios Α. Dimopoulos(Korea University), André Abdo(Universidade de São Paulo), S. Vincent Rajkumar(WinnMed), Tatiana Shelekhova, Iara Gonçalves(Hospital de Câncer de Barretos), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Fredrik Schjesvold(Oslo University Hospital), Chantana Polprasert(Chulalongkorn University), Mário Mariz(Instituto Português de Oncologia Francisco Gentil), Roman Hájek(University Hospital Ostrava), Philippe Moreau(Centre National de la Recherche Scientifique), Andrew Spencer(The Alfred Hospital), Vânia Hungria(Faculdade de Ciências Médicas da Santa Casa de São Paulo), Ajai Chari(University of California, San Francisco)
Cited by 70
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k